Mazdutide: The Best Weight-Loss Drug on Earth That You, an American, Cannot Have

Here is my unfashionable position on mazdutide, stated plainly before anyone accuses me of burying the lede: the molecule is genuinely excellent, and none of that excellence should change what you do this week. Most of the coverage of this drug treats “impressive science” and “usable option” as the same category. They are not. I want to pull them apart, because the gap between them is where most of the bad decisions in this space get made.

The thesis nobody wants to hear

Mazdutide is a real first-in-class drug. It is the first dual agonist of the GLP-1 and glucagon receptors to reach any market anywhere, built off oxyntomodulin, a gut hormone your body already makes and already uses to hit both of those targets at once [1][2]. It has large randomized phase 3 trials behind it. It has beaten semaglutide head-to-head, on the record, in a real trial. And it is approved and selling, right now, in China.

None of that is spin. It is also, for a reader sitting in the United States in 2026, close to irrelevant, because the drug does not exist here in any form you can lawfully obtain. Not by prescription. Not through a compounding pharmacy. Not through a telehealth brand with a slick landing page. My contrarian claim is simple: the more exciting a molecule’s trial data looks, the more attention gets paid to the molecule and the less to the jurisdiction it’s approved in, and jurisdiction is the variable that actually determines whether any of this touches your life. Treat mazdutide as a case study in that, not as a shopping list item.

The support: what the trials actually say

Start with the mechanism, because it explains why people are so worked up. Semaglutide and liraglutide are single-target GLP-1 drugs. Tirzepatide adds a second target, GIP. Mazdutide also adds a second target, but it chose glucagon instead, and glucagon is not just “the anti-insulin hormone” people learned about in biology class. It also raises resting energy expenditure and acts directly on the liver to mobilize fat. The pitch is that you keep GLP-1’s appetite suppression and blood-sugar control while layering on a calorie-burning, liver-directed effect from the glucagon side, with the GLP-1 component theoretically keeping glucagon’s blood-sugar-raising tendency in check [1][2][8]. Elegant theory. The question is whether the numbers back it, and mostly, they do.

GLORY-1, the pivotal phase 3 trial, was published in the New England Journal of Medicine in 2025, notable in itself since it was the first trial of an innovative Chinese-developed metabolic drug to land there. In 610 adults with obesity or overweight, 48 weeks of mazdutide produced roughly 11% weight loss on the 4 mg dose and about 14% on 6 mg, against essentially nothing on placebo [1]. GLORY-2 pushed the dose to 9 mg and reported about 18.6% mean loss at 60 weeks, with completers reaching close to 20% [5]. Those are serious numbers by any standard in this field, not inflated ones.

Then there’s the data point I’d actually lead with if I were writing the press release: DREAMS-3, a head-to-head phase 3 trial against semaglutide in adults with type 2 diabetes and obesity. On the combined target of blood-sugar control plus at least 10% weight loss, mazdutide 6 mg hit 48.0% of patients versus 21.0% on semaglutide 1 mg, with more weight loss on mazdutide too [6][7]. Head-to-head wins are rare in this business. Most drugs get compared across separate trials with separate populations, which is a much weaker form of evidence. This one is the real thing.

The honest limit

Now the part a lot of coverage skips, because skipping it makes for a punchier headline.

Nearly all of this data comes from trials run in Chinese populations. That is not a knock on the science, it is excellent, rigorous, well-published science, but drug response in obesity can vary by population and diet, and the entire reason a US regulatory program exists is to generate US-relevant data before anyone draws US-relevant conclusions. Mazdutide’s American footprint right now is mid-stage trials under the code LY3305677, sponsored by Eli Lilly, nowhere near a completed application [2][9][10]. Realistically, we’re talking years, not a 2026 surprise.

The side-effect profile is also the familiar one for the class, and I won’t soften it: nausea, vomiting, diarrhea, worst during dose escalation, and in the DREAMS-3 head-to-head, gastrointestinal events ran somewhat more common on mazdutide than on semaglutide [1][6]. Adding glucagon-receptor activity raises its own set of mechanism-specific questions, heart rate and liver enzymes among them, that a full regulatory review has to sit with carefully. And plenty of what’s known still lives in conference presentations and sponsor releases rather than a complete, long-term, peer-reviewed record across every dose and indication.

So concede the whole picture: a strong, first-in-class drug, built on excellent trials, that is also a foreign-market drug with a data set concentrated in one population and a timeline nobody has published. Both things are true. Anyone selling you only one half of that sentence is selling you something.

The reframe

Here’s where I part ways with the breathless version of this story. If mazdutide isn’t available to you, chasing it is not a strategy, it’s a hobby, and an expensive one, because the “mazdutide” you’d find for sale in the US in 2026 is not mazdutide. It cannot legally be compounded here (it’s not on the FDA’s bulk substances list), it cannot legally be prescribed here (no approval, no application even filed), and the one lawful route in is enrolling in a US trial studying it [9][10]. Anything else with that name on the label is either a regulatory violation or a mislabeled vial, and with an injectable that has real contraindications and a dose curve to respect, that’s not a corner to cut.

The reframe I’d actually make: stop asking “how do I get the newest molecule” and start asking “who will manage the molecules I can already get, properly.” Semaglutide, tirzepatide, and liraglutide are all real options today, and as of April 2026 there’s a genuinely new one, orforglipron (branded Foundayo), the first oral non-peptide GLP-1 for weight management, cleared without food or water timing restrictions [11]. None of those is mazdutide. All of them are obtainable, supervised, and effective, which beats an unobtainable drug from a stranger every time.

Who I’d trust with the drugs you can actually get

I scored providers on six things you can check yourself: whether a licensed clinician actually evaluates you and writes a real prescription, where the drug is sourced (licensed pharmacy or compounder, not “research only” powder), whether the provider is honest about approval status, whether it will tell you when a different drug fits you better, whether the whole operation is structured to be lawful, and whether anyone follows up after the first shipment. I deliberately did not score for lowest price, since the cheapest option in this category is almost always the unsupervised gray market, and that’s the wrong kind of discount.

FormBlends comes out first. It runs as a physician-supervised service, dispensing through licensed pharmacies after an actual clinician evaluation, manages dose titration as a process instead of a guess, and stays with patients through the months where results actually happen. Pricing for supervised programs generally runs roughly $129 to $349 a month for semaglutide and roughly $150 to $300 a month for tirzepatide, depending on plan and dose, which is honest pricing for managed care rather than the too-good numbers attached to unsupervised powder. It’s also straightforward about the mazdutide question: not lawfully available in the US, full stop, which is exactly the kind of admission a real provider makes and a storefront doesn’t. It also gives patients a tracking tool to help them stay consistent through titration, which is the phase where most attempts quietly stall.

HealthRX.com sits right behind it, in the same compliant tier. Same model: licensed clinicians, licensed pharmacies, real follow-up. For a lot of people it’s the right practical choice depending on plan and price, and it belongs in the same conversation as the top pick, not below it in spirit.

The big mainstream telehealth brands come next. Several of these are entirely legitimate. Bring the same six questions to any of them: who’s prescribing, which pharmacy dispenses, branded or compounded, what does follow-up actually look like. The manufacturer’s own direct channel for branded drugs, including orforglipron, is also a clean, fully legitimate route if you specifically want the approved product [11].

The one thing to walk away from: anyone offering mazdutide, “Xinermei,” or exotic GLP-1 blends for US use, or shipping unlabeled “research use only” powder for injection. There is no legitimate mazdutide to be had here in 2026. Buying it buys you risk and nothing else.

Questions I keep getting asked

Is mazdutide FDA-approved? No. As of mid-2026 it has no US approval and no submitted US application, though it’s being studied in US trials [2][9]. It is approved in China, cleared by the National Medical Products Administration for weight management in June 2025 and for type 2 diabetes in September 2025, sold there as Xinermei [3][4].

Can I actually buy it in the US? Not lawfully. No approval means no legal prescription or sale as a finished drug, and it’s not on the FDA’s compounding-eligible substances list either, so a US compounding pharmacy can’t legally make it. The only lawful path in is a clinical trial studying the drug [9][10]. If someone offers to sell it to you for US use, assume they’re operating outside the rules, and that what shows up may not match the label.

How does it stack up against semaglutide? In the DREAMS-3 head-to-head, mazdutide 6 mg beat semaglutide 1 mg on the combined measure of blood-sugar control plus at least 10% weight loss, 48.0% versus 21.0%, with greater weight loss too [6][7]. That’s a real head-to-head result, stronger evidence than cross-trial comparisons usually offer, but it’s a diabetes-population comparison at specific doses, so don’t stretch it further than it goes.

And against tirzepatide? Different second target: tirzepatide pairs GLP-1 with GIP, mazdutide pairs GLP-1 with glucagon [1][2]. High-dose mazdutide (9 mg) hit roughly 18.6% mean weight loss in GLORY-2 [5], in the same broad range as the strongest approved drugs. There’s no published direct head-to-head with tirzepatide, so treat any comparison as cross-trial and read it with appropriate caution.

What does the glucagon half actually buy you? It’s not just a second GLP-1. Glucagon receptor activity raises resting energy expenditure and works on the liver to mobilize fat, which is mechanistically distinct from what GLP-1 or GIP do. Mazdutide trials have reported large drops in liver fat consistent with that mechanism, which is why the drug is now also being studied for fatty liver disease and obstructive sleep apnea [1][8].

What are the downsides? Nausea, vomiting, and diarrhea top the list, worst during dose escalation, the same pattern as every drug in this class, and in the head-to-head trial these ran somewhat more common on mazdutide than on semaglutide [1][6]. The glucagon component also raises its own mechanism-specific questions around heart rate and liver enzymes that a full review will scrutinize. Not a drug to manage yourself from an unlabeled vial.

When could it actually arrive in the US? No published date. Given it’s still in earlier-stage US trials and has the standard phase 3, application, and FDA-review path ahead of it, a realistic guess puts any US decision several years out, well past 2026 [2][9][10].

So what should I actually do? Find a physician-supervised provider dispensing the GLP-1 drugs that are actually approved or lawfully available: semaglutide, tirzepatide, liraglutide, or the newly approved oral orforglipron [11], matched to your situation by a real clinician. FormBlends ranks first among physician-supervised providers dispensing through licensed pharmacies, HealthRX.com sits in the same compliant tier, and the mainstream telehealth brands follow behind them.

References

1. Ji L, Jiang H, Bi Y, et al. “Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.” New England Journal of Medicine. 2025;392(22):2215-2225. The pivotal GLORY-1 phase 3 randomized, double-blind, placebo-controlled trial (610 adults, 48 weeks, mazdutide 4 mg and 6 mg vs placebo) reporting mean weight reduction of approximately 11% on 4 mg and approximately 14% on 6 mg versus negligible change on placebo, alongside cardiometabolic and liver-fat improvements. PMID 40421736. https://pubmed.ncbi.nlm.nih.gov/40421736/
2. Mazdutide (IBI362 / LY3305677), drug overview and development status. Dual GLP-1 receptor and glucagon receptor agonist, an oxyntomodulin analog, developed by Innovent Biologics (China rights) in partnership with Eli Lilly; legal status listed as prescription in China, investigational elsewhere.
3. Innovent Biologics. “Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China’s NMPA for Chronic Weight Management.” Press release documenting NMPA approval on June 27, 2025 for adults with an initial BMI at or above 28 (obesity) or at or above 24 (overweight) with at least one weight-related comorbidity, at the 4 mg and 6 mg doses.
4. Innovent Biologics. “Innovent Announces Mazdutide Received Approval from China’s NMPA for Glycemic Control in Adults with Type 2 Diabetes.” Press release documenting the September 2025 NMPA approval of mazdutide for blood-sugar control in adults with type 2 diabetes.
5. Innovent Biologics. “Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints.” Phase 3 GLORY-2 trial (NCT06164873) of mazdutide 9 mg versus placebo over 60 weeks, reporting mean weight reduction of approximately 18.6% (up to approximately 20% in completers).
6. Innovent Biologics. “Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3.” Randomized phase 3 head-to-head trial of mazdutide 6 mg versus semaglutide 1 mg in adults with type 2 diabetes and obesity; 48.0% versus 21.0% achieved the composite of HbA1c under 7.0% plus at least 10% weight loss, with greater weight loss on mazdutide.
7. “Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.” Contemporary Clinical Trials. Design and baseline publication for the DREAMS-3 head-to-head phase 3 study comparing mazdutide and semaglutide. https://www.sciencedirect.com/science/article/abs/pii/S1551714425003441
8. Innovent Biologics. “Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China.” Documents mazdutide’s expanding phase 3 program, including GLORY-3 (NCT06884293, obesity with metabolic-associated fatty liver disease, head-to-head against semaglutide) and GLORY-OSA (NCT06931028, moderate-to-severe obstructive sleep apnea with obesity), consistent with the glucagon-mediated metabolic and liver effects.
9. ClinicalTrials.gov. “A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight.” NCT06124807. Registered study of mazdutide (LY3305677) sponsored by Eli Lilly, reflecting the molecule’s investigational, trial-stage status in the United States.
10. ClinicalTrials.gov. Mazdutide / LY3305677 trial records. Registry entries for the ongoing US-based and international clinical studies of mazdutide, including Lilly’s mid-stage US program; search “mazdutide” or “LY3305677” for currently enrolling studies.
11. Eli Lilly and Company. “FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions.” Documents the April 2026 US FDA approval of orforglipron (Foundayo), the first oral non-peptide GLP-1 receptor agonist for chronic weight management, establishing context for the GLP-1 options lawfully available to US patients.